Develops targeted oncology therapies including an approved menin inhibitor for genetically defined leukemias.
Develops targeted oncology therapies including an approved menin inhibitor for genetically defined leukemias.
Revuforj, approved in 2024 for relapsed acute leukemia with a certain gene change, is its own product, so sales rest on a small number of specialist cancer centres. Axatilimab, a graft-versus-host disease antibody, is developed and sold in partnership with Incyte.
Moat: narrow (IP / patents, regulatory licence). First approved menin inhibitor for a genetically defined leukemia subtype, with an Incyte GvHD partnership.
Headquarters: Waltham, Massachusetts, US · Founded: 2005 · Employees: 298
Size Syndax Pharmaceuticals (SNDX) is a United States Health Care company (Biotechnology) with a market value of $771M, the 2398th largest of 3,085 United States companies the cockpit tracks. Shares closed at $8.56 on 18 Nov 2026.
Performance Over six months the shares fell 57.5%, against -12.2% for the median peer and -2.2% for the United States market (cap-weighted) — lowest of 19 in its peer set.
Growth Revenue grew 159.7% over the last twelve months (peer median +5.2%); the operating margin is -61.7% (peer median -113.3%).
Valuation It trades at 3.2× enterprise value to sales against a peer median of 6.8× (3rd cheapest of 17).
Capital Return on invested capital runs 103.9 points below its cost of capital (6.6% WACC).
Credit Syndax Pharmaceuticals has 1 bond outstanding ($250M).
Short interest Short interest is 21.0% of the free float (30 Oct 2026).
Next results Next results expected around 2 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $290M | $172M | $23.7M | $0 | $0 |
| Revenue growth | — | +628% | — | — | — |
| Gross profit | $267M | $165M | $22.8M | -$12,000 | -$454,000 |
| EBITDA | -$179M | -$273M | -$340M | -$230M | -$151M |
| Net income | -$209M | -$285M | -$319M | -$209M | -$149M |
| Free cash flow | -$177M | -$323M | -$275M | -$161M | -$134M |
| Capital expenditure | $96,000 | $187,000 | $0 | $0 | $0 |
| Total debt | $589M | $345M | $346M | $1.64M | $1.16M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Syndax Pharmaceuticals SNDX | $771M | -57% | +160% | -62% | 3.2× | n/a |
| Kura Oncology KURA | $674M | -29% | -24% | -394% | 2.6× | n/a |
| Incyte INCY | $24.0B | +21% | +25% | 12% | 3.4× | 14.2% |
| Novartis NOVN.SW | $285B | +11% | -4% | 30% | 6.2× | 1.6% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | SNDX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -35.4% | -6.2% | lowest of 21 |
| 6-month return | -57.5% | -12.2% | lowest of 19 |
| Distance from 52-week high | -66.5% | -44.9% | 2nd lowest of 21 |
| Revenue growth (TTM) | +159.7% | +5.2% | 4th highest of 15 |
| Operating margin | -61.7% | -113.3% | 8th highest of 17 |
| EV / Sales | 3.2× | 6.8× | 3rd cheapest of 17 |
| ROIC minus cost of capital | -103.9 pp | -11.1 pp | lowest of 10 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Syndax Pharmaceuticals SNDX | United States | $771M | -57% | +160% | -62% | 3.2× | n/a | n/a |
| Monte Rosa Therapeutics GLUE | United States | $775M | -51% | -61% | -214% | 3.3× | n/a | n/a |
| Nanjing Leads Biolabs 9887.HK | Hong Kong | $764M | -50% | n/a | -108% | 21.1× | n/a | n/a |
| Inventiva IVA.PA | France | $763M | -36% | -100% | -307,063% | 12,169.8× | n/a | n/a |
| Wuhan Keqian Biology 688526.SS | China | $780M | -24% | -22% | 20% | 4.4× | 7.8% | +2.4% |
| Aura Biosciences AURA | United States | $743M | -4% | n/a | n/a | n/a | n/a | n/a |
| Beijing SL Pharmaceutical 002038.SZ | China | $736M | -20% | -4% | -119% | 6.9× | -13.5% | -10.9% |
| MeiraGTx MGTX | United States | $813M | -13% | +1,366% | 44% | 1.9× | n/a | n/a |
| Apnimed APMD | United States | $726M | n/a | +380% | -140% | 10.8× | n/a | n/a |
| R&G PharmaStudies 301333.SZ | China | $722M | -11% | +21% | 11% | 3.4× | 17.3% | +11.8% |
| Shaanxi Micot Pharmaceutical Technology 2335.HK | Hong Kong | $715M | n/a | n/a | n/a | n/a | n/a | n/a |
| Attovia Therapeutics ATTO | United States | $710M | +1,325% | n/a | -5,945% | 220.7× | n/a | n/a |
| Solid Biosciences SLDB | United States | $709M | -2% | n/a | n/a | n/a | n/a | n/a |
| Oxford BioMedica OXB.L | United Kingdom | $841M | -15% | +16% | -18% | 4.1× | n/a | n/a |
| Prime Medicine PRME | United States | $695M | +35% | +18% | -2,584% | 105.4× | n/a | n/a |
| Verastem VSTM | United States | $866M | +66% | +650% | -194% | 8.2× | n/a | n/a |
| Anhui Wanbang Pharmaceutical Technology 301520.SZ | China | $684M | +74% | -15% | -8% | 14.7× | 44.8% | +14.7% |
| Peptidream 4587.T | Japan | $878M | -3% | +14% | -18% | 6.6× | n/a | n/a |
| Kura Oncology KURA | United States | $674M | -29% | -24% | -394% | 2.6× | n/a | n/a |
| Steminent Biotherapeutics 7729.TWO | Taiwan | $668M | +292% | n/a | n/a | n/a | n/a | n/a |
| Alphamab Oncology 9966.HK | Hong Kong | $666M | -38% | -32% | -38% | 6.7× | n/a | n/a |
Syndax Pharmaceuticals has 1 bond outstanding with $250M face value.